Apcer Life Sciences
Apcer Life Sciences is recorded as a service provider in 5 clinical trials. Explore its recorded services, study phases and therapeutic areas, with trial-level operational learnings where available.
Clinical trial experience
Showing 5 of 5 trials · Latest update first
An Efficacy and Safety, Phase III, Multi-center, Double-Blind, Randomized Controlled Study Comparing 2 Active Doses of CYB003 and Placebo in Eligible Participants with Major Depressive Disorder (EMBRACE)
Sponsor Cybin IRL Limited
- Start (EU)
- Latest update
- Estimated end
Multi-Center, Placebo-Controlled, Phase 3 Study of Etripamil Nasal Spray (NS) in Patients with Atrial Fibrillation and Rapid Ventricular Rate (RVR). The ReVeRA-301 Trial.
Sponsor Milestone Pharmaceuticals Inc.
- Start (EU)
- Latest update
- Estimated end
A Phase 2a, Open-label, Single-Arm Study Investigating Tolerability of IV/IM Administration of RetinolX (retinol palmitate) in Preterm Infants, and Measuring Serum Levels of Retinol, Retinol Palmitate and Retinol Binding Protein (RBP4) (PARELETO - Trial)
Sponsor Aspire Pharma Limited
- Start (EU)
- Latest update
- Estimated end
- Not reported
A Phase III Long-Term Extension Trial with Optional Additional Doses of CYB003 to Assess the Safety and Long-term Efficacy in Participants with Major Depressive Disorder (EXTEND)
Sponsor Cybin IRL Limited
- Start (EU)
- Latest update
- Estimated end
The NODE-202 Study Multi-Center, Multi-National, Open-Label, Efficacy and Safety Study of Etripamil Nasal Spray in Pediatric Patients with Paroxysmal Supraventricular Tachycardia
Sponsor Milestone Pharmaceuticals Inc.
- Start (EU)
- Latest update
- Estimated end
Questions about this trial experience
What services are recorded for Apcer Life Sciences?
The 2026-10-09 snapshot links Apcer Life Sciences to 5 distinct CTIS trials. Recorded services include Safety reporting & pharmacovigilance. These are study-specific roles, not a complete or independently verified capability catalogue.
Which therapeutic areas and study phases are recorded for Apcer Life Sciences?
The most frequently recorded therapeutic areas are Cardiology, Psychiatry, Respiratory. Recorded phases include Phase 3, Phase 2. Use the filters to inspect the supporting studies; missing tags are not evidence of absent experience.
In which countries are trials linked to Apcer Life Sciences conducted?
The linked trials record locations in 7 countries, including Germany, Poland, Czechia, Greece, Ireland. These are trial locations, not confirmed office locations or countries where Apcer Life Sciences delivered services.
What can this page tell me about Apcer Life Sciences's trial experience?
Browse 5 distinct trials with recorded roles, sponsor names, available study dates and links to CTIS source records. No trial-level operational findings are recorded in this snapshot. Trial counts and findings do not measure the provider’s performance or establish responsibility for study outcomes.
About this data & company names
One current approved profile per CTIS trial. Services reflect recorded roles, not a complete capability catalogue or a performance ranking. Missing tags mean the information was not recorded. Country tags describe trial locations, not the provider’s service territory.
Start is the reported EU start date; latest update is the CTIS publication date; estimated end is the reported global estimate, which may be in the past. Missing dates are shown as “Not reported”. Operational learnings describe the trial as a whole and do not establish the provider’s responsibility.
Clear service synonyms are grouped; otherwise the source label is retained. Service tags show the recorded roles for each trial. This page groups 2 recorded name variants under Apcer Life Sciences. Legacy brands remain separate unless explicitly matched in the name registry.
View recorded company names
- APCER Life Sciences, Inc.
- Apcer Life Sciences Limited